Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma
Enrichment of CD7<sup>+</sup>CXCR3<sup>+</sup> CAR T-cells alongside elevated NKG2D expression in R, in contrast to higher LAG3 and CD71 in NR, emerged as potentially robust correlates of therapeutic outcome. Although derived from a small, hypothesis-generating cohort, these findings suggest that targeted analysis of IP composition may inform the development of biomarker-driven strategies to optimize CAR T-cell products and improve the likelihood of durable remission in R/R DLBCL.
Authors
- Bernhard Gentner (ORCID: https://orcid.org/0000-0001-6024-4718)
- Giuseppe Pantaleo (ORCID: https://orcid.org/0000-0003-3651-2721)
- Douglas Daoudlarian
- George Coukos (ORCID: https://orcid.org/0000-0001-8813-7367)
- Michel Obéid (ORCID: https://orcid.org/0000-0003-2095-2677)
- Craig Fenwick (ORCID: https://orcid.org/0000-0002-9435-0110)
- Robin Bartolini (ORCID: https://orcid.org/0000-0001-6875-6734)
- Victor Joo
- Matthieu Perreau (ORCID: https://orcid.org/0000-0003-2110-2244)
- R Stadelmann
- Alessandra Noto (ORCID: https://orcid.org/0000-0003-2813-9488)
- Lionel Trueb
- Caroline Arber (ORCID: https://orcid.org/0000-0001-6440-9970)
Institutions
- Centre Hospitalier Universitaire Vaudois (CH)
- Ludwig Cancer Research (CH)
- Swiss Cancer Center Léman (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1016/j.annonc.2025.03.011
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Gilead Sciences
- Celgene
- Ludwig Institute for Cancer Research
- Moderna
- Université de Lausanne
- Centre Hospitalier Universitaire Vaudois